| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04781088) | Floor Backes, MD | 2021-09-01 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors (NCT04616534) | National Cancer Institute (NCI) | 2021-06-01 |
| Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04753216) | Northwestern University | 2021-03-16 |
| ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer (NCT04055649) | Ira Winer | 2020-01-21 |
| AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04019288) | M.D. Anderson Cancer Center | 2019-12-03 |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT03907527) | Precigen, Inc | 2019-04-30 |
| Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma (NCT03610490) | M.D. Anderson Cancer Center | 2018-10-16 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03587311) | National Cancer Institute (NCI) | 2018-10-12 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (NCT03449108) | M.D. Anderson Cancer Center | 2018-04-27 |
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT03206047) | National Cancer Institute (NCI) | 2017-11-08 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 (NCT02650986) | Roswell Park Cancer Institute | 2017-07-14 |
| Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer (NCT02898207) | National Cancer Institute (NCI) | 2017-05-19 |
| Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT03026062) | M.D. Anderson Cancer Center | 2017-05-18 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer (NCT02298959) | National Cancer Institute (NCI) | 2015-04-08 |
| Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer (NCT01970722) | City of Hope Medical Center | 2014-05-19 |
| Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers (NCT02020707) | Mayo Clinic | 2014-02-24 |